Pharmacogénétique et pharmacogénomie
Author:
Le Morvan V.,Robert J.
Reference25 articles.
1. Watson MA, Stewart RK, Smith GB et al. (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275–80
2. Teh LK, Bertilsson L (2012) Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 27: 55–67
3. Kimchi-Sarfaty C, Oh JM, Kim IW et al. (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525–8
4. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12: 555–8
5. Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65: 5481–4